Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEM-AMI OUTCOME TRIAL
2013-001772-38Phase 3Terminated
- Sponsor
- Fondazione ANMCO
- Start
- May 2013
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in myocardial infarction (MI) and left ventricular systolic dysfunction (LVSD) comparing Filgrastim plus standard of care with Standard of care alone (2 arms). Primary endpoint: Primary composite endpoint. Started May 2013; status: terminated.
02
Drugs
filgrastim
03
Conditions
myocardial infarction (MI)left ventricular systolic dysfunction (LVSD)
Beyond the preview
Go deeper on 2013-001772-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001772-38.